查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1801791

2025-2035年全球宏基因体定序市场

Global Metagenomic Sequencing Market 2025-2035
出版日期: | 出版商: Orion Market Research | 英文 235 Pages | 商品交期: 2-3个工作天内

价格

宏基因组定序市场规模、份额和趋势分析报告，按应用（药物发现、临床诊断、土壤微生物组、工业应用、生态和环境以及兽医）、按产品和服务（试剂和耗材、仪器、测序服务、分析和数据解释解决方案）、按技术（16s RNA定序、散弹枪宏基因组定序、全基因组定序和从头组装、宏转录组学）和按工作流程（样本製备、定序、数据处理和分析）、预测期（2025-2035）

行业概览

目录

第一章：报告摘要

  • 当前行业分析和成长潜力展望
  • 全球宏基因体定序市场销售分析 - 技术 | 产品与服务 | 工作流程 | 应用（百万美元）
  • 主要国家/地区宏基因组定序市场销售表现
  • 研究方法
  • 主要研究方法
  • 次要研究方法
  • 市场概况

第二章：市场概况与洞察

  • 研究范围
  • 分析师洞察和当前市场趋势
    • 宏基因体定序产业关键趋势
    • 市场建议
  • 宏基因体定序市场的波特五力分析
    • 竞争对手
    • 新进入者的威胁
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁

第三章：市场决定因素

  • 市场驱动因素
    • 全球宏基因体定序市场的驱动因素：影响分析
  • 市场痛点与挑战
    • 全球宏基因体定序市场的限制：影响分析
  • 市场机会

第四章：竞争格局

  • Competitive Dashboard - Metagenomic Sequencing Market Revenue and Share by Manufacturers
  • Metagenomic Sequencing Product Comparison Analysis
  • Top Market Player Ranking Matrix
  • 重点公司分析
    • BGI Genomics
    • Illumina, Inc.
    • Oxford Nanopore Technologies plc.
    • QIAGEN GmbH
    • Thermo Fisher Scientific Inc.
  • Top Winning Strategies by Market Players
    • Merger and Acquisition
    • Product Launch
    • Partnership And Collaboration

第五章：全球宏基因体定序市场销售分析（依技术划分）（百万美元）

  • 16s RNA定序
  • 散弹枪宏基因组定序
  • 全基因组定序与从头组装
  • 宏转录组学

第六章：全球宏基因体定序市场销售分析（按产品和服务划分）（百万美元）

  • 试剂和耗材
  • 仪器
  • 定序服务
  • 分析和数据解释解决方案

第七章：全球宏基因体定序市场销售分析（依工作流程划分）（百万美元）

  • 样品製备
  • 定序
  • 数据处理与分析

第八章：全球宏基因体定序市场销售分析（按应用划分）（百万美元）

  • 药物研发
  • 临床诊断
  • 土壤微生物组
  • 工业应用
  • 生态与环境
  • 兽医

第九章：区域分析

  • 北美宏基因体定序市场销售分析 - 技术 | 产品与服务 | 工作流程 | 应用 | 国家（百万美元）
  • 北美的宏观经济因素
    • 美国
    • 加拿大
  • 欧洲宏基因体定序市场销售分析 - 技术 | 产品与服务 | 工作流程 | 应用 | 国家（百万美元）
  • 欧洲的宏观经济因素
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 俄罗斯
    • 欧洲其他地区
  • 亚太宏基因体定序市场销售分析 - 技术 | 产品与服务 | 工作流程 | 应用 | 国家（百万美元）
  • 亚太地区的宏观经济因素
    • 中国
    • 日本
    • 韩国
    • 印度
    • 澳洲和纽西兰
    • 东协国家（泰国、印尼、越南、新加坡等）
    • 亚太其他地区
  • 世界其他地区宏基因组定序市场销售分析 - 技术 | 产品与服务 | 工作流程 | 应用 | 国家（百万美元）
  • 世界其他地区的宏观经济因素
    • 拉丁美洲
    • 中东和非洲

第十章：公司简介

  • Agilent Technologies, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Azenta Life Sciences
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Baseclear B.V.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • BGI Group
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Biomarker Technologies (BMKGENE)
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Biomatters Ltd. (Geneious)
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Bio-Rad Laboratories, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Cd Genomics
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Celemics, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Cosmosid Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • DNAnexus, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Eurofins Scientific SE
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • F. Hoffmann-La Roche Ltd.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Illumina, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Macrogen, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • MGI tech GmbH, Ltd.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Microsynth AG
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • MR DNA (Molecular Research LP)
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • New England Biolabs, Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Novogene Co., Ltd.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Oxford Nanopore Technologies plc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Pacific Biosciences Of California, Inc. (Pacbio)
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • QIAGEN GmbH
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Source BioScience UK Ltd.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Takara Bio Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Thermo Fisher Scientific Inc.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Zymo Research Corp.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
Product Code: OMR2028456

Metagenomic Sequencing Market Size, Share & Trends Analysis Report by Application(Drug Discovery, Clinical Diagnostic, Soil Microbiome, Industrial Applications, Ecological and Environmental and Veterinary), by Product & Service (Reagents and Consumables, Instruments, Sequencing Services, and Analysis and Data Interpretation Solutions), by Technology (16s RNA Sequencing, Shotgun Metagenomic Sequencing, Whole-Genome Sequencing and De Novo Assembly, and Metatranscrigptomics), and by Workflow (Sample Preparation, Sequencing, and Data Processing and Analysis), Forecast Period (2025-2035)

Industry Overview

Metagenomic sequencing market was valued at $2.2 billion in 2024 and is projected to reach $13.7 billion by 2035, growing at a CAGR of 17.7% during the forecast period (2025-2035). The metagenomic sequencing sector is experiencing sustained growth, largely propelled by advancements in next-generation sequencing technologies that have significantly enhanced accuracy, processing speed, and cost-efficiency, facilitating broader and more rapid adoption across applications. The increasing emphasis on early disease detection and personalized medicine supports the accelerating acceptance of technology. There are more investments in microbiome research, both within healthcare and environmental research, that are stimulating market growth, government stimulus funding, and public/private partnerships promoting innovation in genomics. The rise of infectious disease outbreaks and antibiotic resistance is driving the need for a more comprehensive microbial profile. Furthermore, the expanding biotechnology and pharmaceutical industries across the globe are acting as a driver of biological impact.

Market Dynamics

Falling Cost of Genome Sequencing

According to the World Intellectual Property Organization (WIPO), in March 2025, the substantial reduction in the cost of whole genome sequencing from approximately $100 million in 2001 to just over $500 million in the US by 2023 has been a pivotal factor in advancing healthcare innovation, significantly enhancing the capacity to identify accurate diagnoses and develop targeted treatment strategies. This dramatic cost reduction is likely to accelerate the adoption of a number of new genomic technologies, including Metagenomic Sequencing, by reducing the cost and facilitating access to high-resolution genomic analysis. While it is essential to provide equitable access to this technology, particularly in low- and middle-income countries, it remains an issue. Ensuring affordability and accessibility is essential for the global expansion of Optical Genome Mapping (OGM), enabling its full potential to support precision medicine and advance genomic research on an international scale.

Advancements in Long-Read Sequencing

Improvements in long-read sequencing technologies are benefiting the metagenomic sequencing industry. Long-read sequencing technologies are advancing metagenomic sequencing efforts by providing additional tools to accurately assemble complex microbial genomes and better identify structural variants in genome sequences. Long-read sequencing methods can recover long genes as full length and resolve very repetitive or very low-abundance sequences, found in many diverse microbiomes (in environmental, clinical, or industrial contexts). Furthermore, longer read lengths can contribute to an improved taxonomic resolution, providing further insights into the structure of metagenomic communities.

Market Segmentation

  • Based on the application, the market is segmented into drug discovery, clinical diagnostics, soil microbiome, industrial applications, ecological and environmental, and veterinary.
  • Based on the product & service, the market is segmented into reagents and consumables, instruments, sequencing services, and analysis and data interpretation solutions.
  • Based on the technology, the market is segmented into 16s RNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing and de novo assembly, and metatranscriptomics.
  • Based on the workflow, the market is segmented into sample preparation, sequencing, and data processing and analysis.

Shotgun Metagenomic Sequencing Segment to Lead the Market

One of the primary drivers of growth in the metagenomic sequencing market is the rising adoption of shotgun metagenomic sequencing. Shotgun metagenomic sequencing provides information about entire populations of microbes, as it sequences every piece of genetic material from a sample. It can be used to detect low-abundance organisms, emerging (novel) pathogens, and antibiotic resistance genes, making it an asset in clinical, environmental, and research contexts. Researchers favour shotgun metagenomic sequencing for its capacity to provide resolution equal to and superior to targeted sequencing methods used for identifying foodborne and bacterial pathogens. Additionally, sequencing costs have decreased globally, and new, stronger bioinformatics tools have enabled broader and quicker uptake across new applications, diagnostics (human and environmental), microbiome research, and epidemiology. For instance, Illumina Inc. has a series of sequencers that are leading the way as a high-throughput shotgun metagenomic sequencing platform. The common denominator for growth in the metagenomic sequencing segment is the need for reliable accuracy and data sources that have density.

Clinical Diagnostic: A Key Segment in Market Growth

As the clinical/diagnostic benchmarking segment develops into a potential dominant driving force behind the metagenomic sequencing market, metagenomic sequencing as a diagnostic platform has the power to detect a wide range of pathogens with no prior knowledge of their presence, identify pathogens, and even indicate a suspected pathogen. The goal here is to enhance patient outcomes by using metagenomic sequencing to inform clinicians of potential treatments to work towards effectively treating infection. Diagnostic metagenomic sequencing can provide clinical insights into antimicrobial resistance, informing the decision-making for clinicians. Additionally, it is an effective diagnostic method of last resort for novel or rare pathogens and for multiple pathogens in patients who are immunocompromised. For instance, devices such as those used by Oxford Nanopore Technologies' MinION sequencing platform are already being embraced for real-time clinical diagnostics. The quickening pace of infectious diseases, the adoption of diagnostic metagenomic sequencing is indeed happening quickly, with known still-growing potential.

Regional Outlook

The global metagenomic sequencing market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Growing Applications in Medical Research and Healthcare in Europe

According to the Association of the British Pharmaceutical Industry (ABPI), in August 2024, highlighted the substantial growth of the global genomics market, driven by its critical applications in medical research and healthcare. The market is projected to expand by £10.75 billion ($11.6 billion) between 2021 and 2025. In the UK, genomics activities have created an estimated total turnover of £2.4 billion ($2.5 billion) in recent years. The UK has emerged as a global leader in genomic capabilities with the support of the Bioindustry Association (BIA), Medicines Discovery Catapult (MDC), and the Wellcome Sanger Institute, which identified over 140 genomics companies in the UK, with an estimated turnover of £2.4 billion ($2.5 billion). The strong genomic ecosystem was important to the UK's response to the COVID-19 pandemic, including the COVID-19 Genomics UK Consortium (COG-UK) and large-scale diagnostics and sequencing on a national level. This strong base, particularly in metagenomic sequencing, is poised for rapid growth as genomic technologies continue to advance and as genomics becomes more widely adopted in both research and clinical diagnostics. This growth will pave the way for innovation and precision medicine on an international scale.

North America Region Dominates the Market with Major Share

The North American market for metagenomic sequencing is experiencing solid expansion as a result of many different factors. The region has a large number of established advanced research agencies. Many biotechnology companies have been established in the area. Public and private sector investments in genomics or precision medicine continue to grow, helping to propel market growth. The rise in prevalence of chronic diseases and infectious diseases is fueling the need to develop novel and advanced diagnostic testing. Policies supporting metagenomic technologies from governments and funding initiatives will facilitate development beyond sequencing technology. The healthcare system in the region is well developed, allowing for early adoption of the latest technology supported by programs and policymakers. The science community around academia and industry promotes collaborations and is helping to deliver scientific advancement more rapidly. Increased awareness of microbial genomics for clinical and environmental applications will assist in sustainable market growth.

Market Players Outlook

The major companies operating in the global metagenomic sequencing market include BGI Genomics, Illumina, Inc., Oxford Nanopore Technologies, QIAGEN N.V., and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

  • In April 2025, Metabolon, Inc., a commercially provides metabolomics solutions that support a variety of life science research, diagnostic, therapeutic product development, and precision medicine applications, announced the launch of a complete microbiome research solution that combines metagenomics sequencing and bioinformatics tools with a new microbiome metabolite panel. Metabolon's new microbiome research solution offers high-quality metagenomic sequencing options, allowing customers to select sequencing methods and depths for seamless integration of their metagenomics data with metabolomic and phenotypic data.
  • In October 2024, Delve Bio, in metagenomic next generation sequencing (mNGS) for infectious diseases, and Broad Clinical Labs (BCL), the leading genome sequencing and testing laboratory, announced a partnership to provide the expertise in neurology, infectious disease, and clinical genomics to scale up metagenomics access for individuals with neurological infections.

The Report Covers:

  • Market value data analysis of 2024 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global metagenomic sequencing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Global Metagenomic Sequencing Market Sales Analysis - Technology | Product & Service | Workflow | Application ($ Million)
  • Metagenomic Sequencing Market Sales Performance of Top Countries
  • 1.1. Research Methodology
  • Primary Research Approach
  • Secondary Research Approach
  • 1.2. Market Snapshot

2. Market Overview and Insights

  • 2.1. Scope of the Study
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Metagenomic Sequencing Industry Trends
    • 2.2.2. Market Recommendations
  • 2.3. Porter's Five Forces Analysis for the Metagenomic Sequencing Market
    • 2.3.1. Competitive Rivalry
    • 2.3.2. Threat of New Entrants
    • 2.3.3. Bargaining Power of Suppliers
    • 2.3.4. Bargaining Power of Buyers
    • 2.3.5. Threat of Substitutes

3. Market Determinants

  • 3.1. Market Drivers
    • 3.1.1. Drivers For the Global Metagenomic Sequencing Market: Impact Analysis
  • 3.2. Market Pain Points and Challenges
    • 3.2.1. Restraints For the Global Metagenomic Sequencing Market: Impact Analysis
  • 3.3. Market Opportunities

4. Competitive Landscape

  • 4.1. Competitive Dashboard - Metagenomic Sequencing Market Revenue and Share by Manufacturers
  • Metagenomic Sequencing Product Comparison Analysis
  • Top Market Player Ranking Matrix
  • 4.2. Key Company Analysis
    • 4.2.1. BGI Genomics
      • 4.2.1.1. Overview
      • 4.2.1.2. Product Portfolio
      • 4.2.1.3. Financial Analysis (Subject to Data Availability)
      • 4.2.1.4. SWOT Analysis
      • 4.2.1.5. Business Strategy
    • 4.2.2. Illumina, Inc.
      • 4.2.2.1. Overview
      • 4.2.2.2. Product Portfolio
      • 4.2.2.3. Financial Analysis (Subject to Data Availability)
      • 4.2.2.4. SWOT Analysis
      • 4.2.2.5. Business Strategy
    • 4.2.3. Oxford Nanopore Technologies plc.
      • 4.2.3.1. Overview
      • 4.2.3.2. Product Portfolio
      • 4.2.3.3. Financial Analysis (Subject to Data Availability)
      • 4.2.3.4. SWOT Analysis
      • 4.2.3.5. Business Strategy
    • 4.2.4. QIAGEN GmbH
      • 4.2.4.1. Overview
      • 4.2.4.2. Product Portfolio
      • 4.2.4.3. Financial Analysis (Subject to Data Availability)
      • 4.2.4.4. SWOT Analysis
      • 4.2.4.5. Business Strategy
    • 4.2.5. Thermo Fisher Scientific Inc.
      • 4.2.5.1. Overview
      • 4.2.5.2. Product Portfolio
      • 4.2.5.3. Financial Analysis (Subject to Data Availability)
      • 4.2.5.4. SWOT Analysis
      • 4.2.5.5. Business Strategy
  • 4.3. Top Winning Strategies by Market Players
    • 4.3.1. Merger and Acquisition
    • 4.3.2. Product Launch
    • 4.3.3. Partnership And Collaboration

5. Global Metagenomic Sequencing Market Sales Analysis by Technology ($ Million)

  • 5.1. 16s RNA Sequencing
  • 5.2. Shotgun Metagenomic Sequencing
  • 5.3. Whole-Genome Sequencing and De Novo Assembly
  • 5.4. Metatranscriptomics

6. Global Metagenomic Sequencing Market Sales Analysis by Product & Service ($ Million)

  • 6.1. Reagents and Consumables
  • 6.2. Instruments
  • 6.3. Sequencing Services
  • 6.4. Analysis and Data Interpretation Solutions

7. Global Metagenomic Sequencing Market Sales Analysis by Workflow ($ Million)

  • 7.1. Sample Preparation
  • 7.2. Sequencing
  • 7.3. Data Processing and Analysis

8. Global Metagenomic Sequencing Market Sales Analysis by Application ($ Million)

  • 8.1. Drug Discovery
  • 8.2. Clinical Diagnostic
  • 8.3. Soil Microbiome
  • 8.4. Industrial Applications
  • 8.5. Ecological and Environmental
  • 8.6. Veterinary

9. Regional Analysis

  • 9.1. North American Metagenomic Sequencing Market Sales Analysis - Technology | Product & Service | Workflow | Application | Country ($ Million)
  • Macroeconomic Factors for North America
    • 9.1.1. United States
    • 9.1.2. Canada
  • 9.2. European Metagenomic Sequencing Market Sales Analysis - Technology | Product & Service | Workflow | Application | Country ($ Million)
  • Macroeconomic Factors for Europe
    • 9.2.1. UK
    • 9.2.2. Germany
    • 9.2.3. Italy
    • 9.2.4. Spain
    • 9.2.5. France
    • 9.2.6. Russia
    • 9.2.7. Rest of Europe
  • 9.3. Asia-Pacific Metagenomic Sequencing Market Sales Analysis - Technology | Product & Service | Workflow | Application | Country ($ Million)
  • Macroeconomic Factors for Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. South Korea
    • 9.3.4. India
    • 9.3.5. Australia & New Zealand
    • 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
    • 9.3.7. Rest of Asia-Pacific
  • 9.4. Rest of the World Metagenomic Sequencing Market Sales Analysis - Technology | Product & Service | Workflow | Application | Country ($ Million)
  • Macroeconomic Factors for the Rest of the World
    • 9.4.1. Latin America
    • 9.4.2. Middle East and Africa

10. Company Profiles

  • 10.1. Agilent Technologies, Inc.
    • 10.1.1. Quick Facts
    • 10.1.2. Company Overview
    • 10.1.3. Product Portfolio
    • 10.1.4. Business Strategies
  • 10.2. Azenta Life Sciences
    • 10.2.1. Quick Facts
    • 10.2.2. Company Overview
    • 10.2.3. Product Portfolio
    • 10.2.4. Business Strategies
  • 10.3. Baseclear B.V.
    • 10.3.1. Quick Facts
    • 10.3.2. Company Overview
    • 10.3.3. Product Portfolio
    • 10.3.4. Business Strategies
  • 10.4. BGI Group
    • 10.4.1. Quick Facts
    • 10.4.2. Company Overview
    • 10.4.3. Product Portfolio
    • 10.4.4. Business Strategies
  • 10.5. Biomarker Technologies (BMKGENE)
    • 10.5.1. Quick Facts
    • 10.5.2. Company Overview
    • 10.5.3. Product Portfolio
    • 10.5.4. Business Strategies
  • 10.6. Biomatters Ltd. (Geneious)
    • 10.6.1. Quick Facts
    • 10.6.2. Company Overview
    • 10.6.3. Product Portfolio
    • 10.6.4. Business Strategies
  • 10.7. Bio-Rad Laboratories, Inc.
    • 10.7.1. Quick Facts
    • 10.7.2. Company Overview
    • 10.7.3. Product Portfolio
    • 10.7.4. Business Strategies
  • 10.8. Cd Genomics
    • 10.8.1. Quick Facts
    • 10.8.2. Company Overview
    • 10.8.3. Product Portfolio
    • 10.8.4. Business Strategies
  • 10.9. Celemics, Inc.
    • 10.9.1. Quick Facts
    • 10.9.2. Company Overview
    • 10.9.3. Product Portfolio
    • 10.9.4. Business Strategies
  • 10.10. Cosmosid Inc.
    • 10.10.1. Quick Facts
    • 10.10.2. Company Overview
    • 10.10.3. Product Portfolio
    • 10.10.4. Business Strategies
  • 10.11. DNAnexus, Inc.
    • 10.11.1. Quick Facts
    • 10.11.2. Company Overview
    • 10.11.3. Product Portfolio
    • 10.11.4. Business Strategies
  • 10.12. Eurofins Scientific SE
    • 10.12.1. Quick Facts
    • 10.12.2. Company Overview
    • 10.12.3. Product Portfolio
    • 10.12.4. Business Strategies
  • 10.13. F. Hoffmann-La Roche Ltd.
    • 10.13.1. Quick Facts
    • 10.13.2. Company Overview
    • 10.13.3. Product Portfolio
    • 10.13.4. Business Strategies
  • 10.14. Illumina, Inc.
    • 10.14.1. Quick Facts
    • 10.14.2. Company Overview
    • 10.14.3. Product Portfolio
    • 10.14.4. Business Strategies
  • 10.15. Macrogen, Inc.
    • 10.15.1. Quick Facts
    • 10.15.2. Company Overview
    • 10.15.3. Product Portfolio
    • 10.15.4. Business Strategies
  • 10.16. MGI tech GmbH, Ltd.
    • 10.16.1. Quick Facts
    • 10.16.2. Company Overview
    • 10.16.3. Product Portfolio
    • 10.16.4. Business Strategies
  • 10.17. Microsynth AG
    • 10.17.1. Quick Facts
    • 10.17.2. Company Overview
    • 10.17.3. Product Portfolio
    • 10.17.4. Business Strategies
  • 10.18. MR DNA (Molecular Research LP)
    • 10.18.1. Quick Facts
    • 10.18.2. Company Overview
    • 10.18.3. Product Portfolio
    • 10.18.4. Business Strategies
  • 10.19. New England Biolabs, Inc.
    • 10.19.1. Quick Facts
    • 10.19.2. Company Overview
    • 10.19.3. Product Portfolio
    • 10.19.4. Business Strategies
  • 10.20. Novogene Co., Ltd.
    • 10.20.1. Quick Facts
    • 10.20.2. Company Overview
    • 10.20.3. Product Portfolio
    • 10.20.4. Business Strategies
  • 10.21. Oxford Nanopore Technologies plc.
    • 10.21.1. Quick Facts
    • 10.21.2. Company Overview
    • 10.21.3. Product Portfolio
    • 10.21.4. Business Strategies
  • 10.22. Pacific Biosciences Of California, Inc. (Pacbio)
    • 10.22.1. Quick Facts
    • 10.22.2. Company Overview
    • 10.22.3. Product Portfolio
    • 10.22.4. Business Strategies
  • 10.23. QIAGEN GmbH
    • 10.23.1. Quick Facts
    • 10.23.2. Company Overview
    • 10.23.3. Product Portfolio
    • 10.23.4. Business Strategies
  • 10.24. Source BioScience UK Ltd.
    • 10.24.1. Quick Facts
    • 10.24.2. Company Overview
    • 10.24.3. Product Portfolio
    • 10.24.4. Business Strategies
  • 10.25. Takara Bio Inc.
    • 10.25.1. Quick Facts
    • 10.25.2. Company Overview
    • 10.25.3. Product Portfolio
    • 10.25.4. Business Strategies
  • 10.26. Thermo Fisher Scientific Inc.
    • 10.26.1. Quick Facts
    • 10.26.2. Company Overview
    • 10.26.3. Product Portfolio
    • 10.26.4. Business Strategies
  • 10.27. Zymo Research Corp.
    • 10.27.1. Quick Facts
    • 10.27.2. Company Overview
    • 10.27.3. Product Portfolio
    • 10.27.4. Business Strategies

LIST OF TABLES

  • 1. Global Metagenomic Sequencing Market Research and Analysis by Technology, 2024-2035 ($ Million)
  • 2. Global 16s RNA Metagenomic Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 3. Global Shotgun Metagenomic Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 4. Global Whole-Genome Sequencing and De Novo Assembly Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 5. Global Metatranscriptomics Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 6. Global Metagenomic Sequencing Market Research and Analysis by Product & Service, 2024-2035 ($ Million)
  • 7. Global Metagenomic Sequencing Reagents and Consumables Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 8. Global Metagenomic Sequencing Instruments Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 9. Global Metagenomic Sequencing Services Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 10. Global Metagenomic Sequencing Analysis and Data Interpretation Solutions Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 11. Global Metagenomic Sequencing Market Research and Analysis by Workflow, 2024-2035 ($ Million)
  • 12. Global Metagenomic Sequencing Sample Preparation Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 13. Global Metagenomic Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 14. Global Metagenomic Sequencing Data Processing and Analysis Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 15. Global Metagenomic Sequencing Market Research and Analysis by Application, 2024-2035 ($ Million)
  • 16. Global Metagenomic Sequencing For Drug Discovery Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 17. Global Metagenomic Sequencing For Clinical Diagnostic Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 18. Global Metagenomic Sequencing For Soil Microbiome Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 19. Global Metagenomic Sequencing For Industrial Applications Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 20. Global Metagenomic Sequencing For Ecological and Environmental Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 21. Global Metagenomic Sequencing For Veterinary Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 22. Global Metagenomic Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 23. North American Metagenomic Sequencing Market Research and Analysis by Country, 2024-2035 ($ Million)
  • 24. North American Metagenomic Sequencing Market Research and Analysis by Technology, 2024-2035 ($ Million)
  • 25. North American Metagenomic Sequencing Market Research and Analysis by Product & Service, 2024-2035 ($ Million)
  • 26. North American Metagenomic Sequencing Market Research and Analysis by Workflow, 2024-2035 ($ Million)
  • 27. North American Metagenomic Sequencing Market Research and Analysis by Application, 2024-2035 ($ Million)
  • 28. European Metagenomic Sequencing Market Research and Analysis by Country, 2024-2035 ($ Million)
  • 29. European Metagenomic Sequencing Market Research and Analysis by Technology, 2024-2035 ($ Million)
  • 30. European Metagenomic Sequencing Market Research and Analysis by Product & Service, 2024-2035 ($ Million)
  • 31. European Metagenomic Sequencing Market Research and Analysis by Workflow, 2024-2035 ($ Million)
  • 32. European Metagenomic Sequencing Market Research and Analysis by Application, 2024-2035 ($ Million)
  • 33. Asia-Pacific Metagenomic Sequencing Market Research and Analysis by Country, 2024-2035 ($ Million)
  • 34. Asia-Pacific Metagenomic Sequencing Market Research and Analysis by Technology, 2024-2035 ($ Million)
  • 35. Asia-Pacific Metagenomic Sequencing Market Research and Analysis by Product & Service, 2024-2035 ($ Million)
  • 36. Asia-Pacific Metagenomic Sequencing Market Research and Analysis by Workflow, 2024-2035 ($ Million)
  • 37. Asia-Pacific Metagenomic Sequencing Market Research and Analysis by Application, 2024-2035 ($ Million)
  • 38. Rest of the World Metagenomic Sequencing Market Research and Analysis by Region, 2024-2035 ($ Million)
  • 39. Rest of the World Metagenomic Sequencing Market Research and Analysis by Technology, 2024-2035 ($ Million)
  • 40. Rest of the World Metagenomic Sequencing Market Research and Analysis by Product & Service, 2024-2035 ($ Million)
  • 41. Rest of the World Metagenomic Sequencing Market Research and Analysis by Workflow, 2024-2035 ($ Million)
  • 42. Rest of the World Metagenomic Sequencing Market Research and Analysis by Application, 2024-2035 ($ Million)

LIST OF FIGURES

  • 1. Global Metagenomic Sequencing Market Share by Technology, 2024 Vs 2035 (%)
  • 2. Global 16s RNA Metagenomic Sequencing Market Share by Region, 2024 Vs 2035 (%)
  • 3. Global Shotgun Metagenomic Sequencing Market Share by Region, 2024 Vs 2035 (%)
  • 4. Global Whole-Genome Sequencing and De Novo Assembly Market Share by Region, 2024 Vs 2035 (%)
  • 5. Global Metatranscriptomics Sequencing Market Share by Region, 2024 Vs 2035 (%)
  • 6. Global Metagenomic Sequencing Market Share by Product & Service, 2024 Vs 2035 (%)
  • 7. Global Metagenomic Sequencing Reagents and Consumables Market Share by Region, 2024 Vs 2035 (%)
  • 8. Global Metagenomic Sequencing Instruments Market Share by Region, 2024 Vs 2035 (%)
  • 9. Global Metagenomic Sequencing Services Market Share by Region, 2024 Vs 2035 (%)
  • 10. Global Metagenomic Sequencing Analysis and Data Interpretation Solutions Market Share by Region, 2024 Vs 2035 (%)
  • 11. Global Metagenomic Sequencing Market Share by Workflow, 2024 Vs 2035 (%)
  • 12. Global Metagenomic Sequencing Sample Preparation Market Share by Region, 2024 Vs 2035 (%)
  • 13. Global Metagenomic Sequencing Market Share by Region, 2024 Vs 2035 (%)
  • 14. Global Metagenomic Sequencing Data Processing and Analysis Market Share by Region, 2024 Vs 2035 (%)
  • 15. Global Metagenomic Sequencing Market Share by Application, 2024 Vs 2035 (%)
  • 16. Global Metagenomic Sequencing For Drug Discovery Market Share by Region, 2024 Vs 2035 (%)
  • 17. Global Metagenomic Sequencing For Clinical Diagnostic Market Share by Region, 2024 Vs 2035 (%)
  • 18. Global Metagenomic Sequencing For Soil Microbiome Market Share by Region, 2024 Vs 2035 (%)
  • 19. Global Metagenomic Sequencing For Industrial Applications Market Share by Region, 2024 Vs 2035 (%)
  • 20. Global Metagenomic Sequencing For Ecological and Environmental Market Share by Region, 2024 Vs 2035 (%)
  • 21. Global Metagenomic Sequencing For Veterinary Market Share by Region, 2024 Vs 2035 (%)
  • 22. Global Metagenomic Sequencing Market Share by Region, 2024 Vs 2035 (%)
  • 23. US Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 24. Canada Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 25. UK Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 26. France Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 27. Germany Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 28. Italy Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 29. Spain Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 30. Russia Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 31. Rest of Europe Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 32. India Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 33. China Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 34. Japan Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 35. South Korea Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 36. Australia and New Zealand Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 37. ASEAN Economies Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 38. Rest of Asia-Pacific Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 39. Latin America Metagenomic Sequencing Market Size, 2024-2035 ($ Million)
  • 40. Middle East and Africa Metagenomic Sequencing Market Size, 2024-2035 ($ Million)